TT5 fundamentals
An in-depth look to XTACY THERAPEUTICS CORP. operating, investing, and financing activities
TT5 free cash flow for Q1 24 is 0 EUR. For 2023, TT5 free cash flow was -56.2 k EUR and operating cash flow was -56.19 k EUR.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM